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OBJECTIVES: Lapatinib is an oral small molecule dual targeted
therapy that binds intracellularly to the ATP binding site of the
EGFR and ErbB2 (HER2) receptors. In the EGF100151 trial,
L+C improved time to progression (TTP) and progression free
survival (PFS) vs C-only in women with ErbB2+ MBC who had
received prior therapy including TZ. Following achievement of
the primary endpoint, enrollment was halted, preventing demon-
stration of a signiﬁcant difference in OS. METHODS: To inform
ongoing analyses of the cost-effectiveness of L+C vs. C-only,
Weibull survival functions for PFS and OS were ﬁtted to observed
failure time data from EGF100151 using Accelerated Failure
Time (AFT) regression. Survival function parameters were esti-
mated using a single regression equation for each outcome with
treatment groups entered as an independent variable. Hazard
Ratios (HRs) for progression and death with L+C were assumed
to be proportionate to HRs for C-only. Expected PFS, OS, and
post-progression survival (PPS) were calculated for each group.
The validity of the Weibull model and PH assumption were
assessed using graphical and analytical methods. RESULTS:
Expected PFS, PPS and OS for L+C were 36.89, 43.78, and 80.67
weeks, respectively. Corresponding values for C-only were 22.49,
45.03, 67.47 weeks, respectively. Graphical tests of transformed
survival functions supported use of Weibull distribution. Corre-
lation tests between the ranked failure times and Schoenfeld
residuals, supremum test for proportional hazards assumption,
and comparisons of HRs for L+C vs. C-only by quarter post-
randomization, provided no strong evidence of non-
proportionality. CONCLUSION: Proportional hazards Weibull
survival models are valid for modeling survival time data in
patients with trastuzumab-refractory ErbB2-overexpressing
MBC receiving L+C versus C-only, and suggest that lapatinib
provides substantial beneﬁt in terms of PFS and OS in patients
with ErbB2+ MBC.
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OBJECTIVE: To compare the risk of cancer between Atorvasta-
tin and Simvastatin users. METHODS: Retrospective cohort
study was conducted in Louisiana Medicaid program from
January 1, 1998 through June 30, 2005. Inclusion criteria were
recipients continuously eligible with no more than two months
gap, a paid claim for statin, and at least 40 years of age. Patients
with diagnosis or drug claim for cancer in the washout period
were excluded. Washout period was deﬁned as a period between
index date minus 12 months and index date plus 18 months.
Statin (Atorvastatin or Simvastatin) users were patients with 300
or more days of supply of statin within 18 month period from the
index date. Patients were then followed for at least six months or
until end of study period. A propensity score-based matching
method was used to match both the groups (1:1 match). Users of
Atorvastatin were compared with the users of Simvastatin as to
their risk of cancer. RESULTS: Each group had 1050 recipients
after matching for comparison. Compared with Atorvastatin
users, Simvastatin users experienced similar cancer risk (OR
1.20, 95% C.I. = 0.78–1.82). CONCLUSION: The data from
present study provides evidence that there is no signiﬁcant dif-
ference in risk of cancer between Atorvastatin and Simvastatin
users.
CANCER—Cost Studies
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OBJECTIVE: To evaluate the budget impact to a health plan
after introducing Ixabepilone as a treatment option for meta-
static breast cancer patients who have previously failed Anthra-
cycline and Taxane based regimens. METHODS: The analysis
was conducted from a U.S. payer’s perspective over a three-year
time horizon. The model speciﬁcally considered 2 segments of
MBC patients for which Ixabepilone is indicated: 1) patients
pretreated with Anthracycline and Taxane (AT_p); and 2)
patients pretreated with Anthracycline, Taxane, and Capecitab-
ine (ATC_p). After combining epidemiological data (SEERs,
NCI), market uptake assumptions from market research fore-
casting, and current drug treatment costs (based on WAC price
and average number of treatment cycles a patient received), the
model estimated the incremental budget impact after adopting
Ixabepilone as a treatment option. The model assumed that
during the ﬁrst year, 9.41% of AT_p patients receive Ixabepilone
and Capecitabine combination therapy; and 62.7% of ATC_p
patients are treated with Ixabepilone monotherapy. A plausible
range of parameter values were considered in the sensitivity
analysis. RESULTS: In a hypothetical health plan with approxi-
mately 0.06% of members estimated to be diagnosed with MBC,
it was assumed that 37% were AT_p and 5% were ATC_p
patients. In the year after introduction of Ixabepilone, the overall
incremental cost per member per month (PMPM) was estimated
to be approximately $0.03. For the AT_p patient segment, the
incremental PMPM cost was estimated to be $0.03. However, for
the ATC_p population, the model estimated a savings of $0.002
in PMPM. The incremental cost per treated MBC member per
year is estimated at $545.29 for Year 1, and $640.76 and
$668.01 for Years 2 and 3, respectively. CONCLUSION: In
patients with MBC who have few viable treatment options after
failing AT or ATC treatments, the budgetary impact of adding
Ixabepilone to a health plan was estimated to be minimal.
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OBJECTIVE: To evaluate the HRU in a supplementary medicine
environment in Brazil comparing intravenous (IV) treatments
used in clinical practice. The health resources utilization (HRU)
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